Trial Profile
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of LY03012 in Healthy Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 01 Jan 2021
Price :
$35
*
At a glance
- Drugs LY 03012 (Primary)
- Indications Pain
- Focus Adverse reactions
- 24 Dec 2020 Results presented in a Luye Pharma Group media release.
- 24 Dec 2020 Status changed to completed, according to a Luye Pharma Group media release.
- 03 Sep 2018 According to a Luye Pharma Group media release, the National Medical Products Administration (NMPA) approved the clinical trials of LY03012.